The following study meticulously investigated the impacts of baclofen on lower urinary tract symptoms in males and females less than and greater than 50 years of age. Baclofen is an agonist to GABA B receptors, mainly used in treating muscle spasticity, but also shown to affect bladder function. This study aimed to establish whether baclofen can reduce urgency, frequency, and overactivity symptoms of the bladder in subjects from different demographics. Quantitatively, ANOVA has been done to compare three groups of data: males and females below 50, males above 50, and females above 50. It was found that there is a significant difference between pre- and post-therapy urinary tract functions, with baclofen having maximum effect on males and females in the higher age group. Results showed the efficiency of the drug baclofen in treating lower urinary tract function but with high predisposition in adults over 50 years. In addition, differences regarding responses between ages and gender showed the need to consider different options for individual patients. The research underlines that gender and age are very relevant when the prescription of baclofen is recommended for symptoms within the lower urinary tract. More studies are necessary to look into combination treatments and long-term effects with a view to maximizing therapeutic benefits.
The issues related to common health impacting patients' quality of life are lower urinary tract illnesses. Varying ages people can undoubtedly be at risk for such severe issues because of certain factors, like neurological disorders like multiple sclerosis, cerebral palsy, and spinal cord injuries. The drug Baclofen is largely administered to cure muscle spasms and nerve pain by blocking nerve activity in the central nervous system. Its effects on the lower urinary system are gaining attention, despite the fact that it is most well-known for treating muscular disorders like multiple sclerosis. Its effects on urinary symptoms that may occur in different age groups include frequent urination, difficulty urinating, and bladder overactivity [1].
One common effect of malfunctioning in the higher motor neurons is spasticity. Both brain and spinal cord traumas can result in spasticity, even though the pathophysiological mechanisms might be varying [2]. Being a potent GABA receptor agonist, baclofen is a useful treatment for spasticity. Orally, baclofen was first used in the early 1970s [3]. Unfortunately, it needs extremely high dosages to bind GABA and pass across the blood-brain barrier because of its poor lipid solubility [4-5]. This results in side effects that make the treatment intolerable, including drowsiness, extreme weakness, dizziness, and psychic disturbances [6]. Baclofen was originally used intraspinal for the treatment of spasticity by Penn and Crone [7].
Since the required dose is 500–100 00 times lower than the effective oral dose, intraspinal administration is harmful. Nowadays, epidural catheters are used to deliver the drug directly into the cerebrospinal fluid area. The amount of drug released is regulated by a motorized pump placed under the skin in the abdomen [1].
Treatment of spasticity becomes crucial as patients' movements become more organized and efficient, their body form becomes less contracted and more normal, their sleep quality improves, their pain or discomfort is alleviated, and their general quality of life improves [8].
Baclofen functions as an agonist of GABA receptors and relaxes muscles by attaching itself to the presynaptic and postsynaptic GABA receptors of motor neurons in the anterior horns of the spinal cord. Presynaptic binding stops the release of neurotransmitters by inhibiting high-voltage calcium channels [9]. By stimulating the inward rectifying potassium channel, postsynaptic binding reduces neuronal excitability [10]. As a result, the original muscle contraction signal is removed. Presynaptic activation appears to be more important for reducing spasticity [11]. Spasticity is often associated with traumatic brain injury (TBI), and intraspinal baclofen injection [ITB] is a successful treatment option for this disease [12].
TBI mostly results in neurogenic hyperactivity, which includes pseudosynergy and detrusor muscle hypoactivity, with regard to lower urinary tract function. When TBI occurs as a suprapontine lesion, it typically decreases central inhibitory mechanisms, which causes the detrusor muscle to become neurogenically hyperactive [13]. If there are no more spinal cord injuries, micturition works in concert because the micturition reflex is managed by the pontine micturition center. The main symptoms of this disease include urgency, urgency, and frequent urinary incontinence [11,14]. Therefore, this research focuses on studying the effects of baclofen on lower urinary tract symptoms across different ages.
Common health issues that impair patients' quality of life include lower urinary tract symptomes, which are more prevalent in those with neurological conditions such multiple sclerosis, cerebral palsy, and spinal cord injuries [1].
The central nervous system's nerve activity is inhibited by the muscle relaxant Baclofen. It is mostly used to treat muscle spasms brought on by diseases such as cerebral palsy, multiple sclerosis, and spinal cord injuries. Apart from its well-established impact on skeletal muscle, baclofen may also have an impact on the lower urinary system, where it may alleviate symptoms related to overactive bladder, frequent urination, and trouble peeing. Even while it works well to relieve spasms, there are currently relatively few studies on how it affects lower urinary tract symptoms in all age groups, thus further research is still needed to fully understand this topic [14].
Baclofen has hazards, particularly for more susceptible populations like the elderly, even if it may be quite helpful in reducing lower urinary tract symptoms in some age groups. Therefore, it should be used with caution, with the need for periodic monitoring of the patient to minimize potential side effects to provide better and safer treatment strategies for patients. Therefore, the research problem lies in the following main question: "What is the effect of baclofen on the lower urinary tract in more detail across different age groups?"
The following sub-questions are derived from this main question:
Is there a significant difference in lower urinary tract function between pre-treatment and post-treatment for males and females below 50 years of age
Is there a significant difference in lower urinary tract function between pre-treatment and post-treatment for males above 50 years of age
Is there a significant difference in lower urinary tract function between pre-treatment and post-treatment for females above 50 years of age
The core objective of this research is: "To investigate the effect of baclofen on the lower urinary tract in more detail across different age groups."
The following sub-objectives comprise this primary goal:
To evaluate the impact of Baclofen treatment on lower urinary tract function across males and females below 50 years of age
To evaluate the impact of Baclofen treatment on lower urinary tract function across males above 50 years of age
To evaluate the impact of Baclofen treatment on lower urinary tract function across females above 50 years of age
Understanding how baclofen affects lower urinary tract symptoms across age groups a problem that many patients with a variety of neurological medical problems face is the significance of this study. Since current studies on the effect of baclofen on these symptoms are scarce, this research provides an opportunity to explore its effects, which can be summarized as follows:
This research is a novel scientific attempt to determine the nature of the association between the two variables and to develop proper scientific recommendations because few studies specifically address the impact of baclofen on lower urinary tract symptoms in different age groups
This study will advance knowledge of how baclofen affects the lower urinary tract in various age groups, which could lead to the creation of safer and more efficient treatment plans
It will also aid in determining the possible adverse effects of baclofen and offer suggestions to healthcare professionals regarding its safer and more efficient usage in the management of neurological disorders-related urine symptoms
As long as it offers scholars and students interested in urology useful literature, suggestions, and crucial ideas for their planned studies, this research also serves as a good reference for subsequent investigations
Literature review
Overview of Baclofen for Spasticity: For more than 60 years, Baclofen has been a therapeutically available medication. It is believed that this GABA derivative works by binding to metabotropic GABAB receptors [15]. Although it can also be used to treat neuropathic pain, it is most frequently used to treat muscle spasms [16-17].
Recent studies that we released suggest that Baclofen might have an analgesic impact on the perception of bladder discomfort [18] that evaluated the effects of routinely used adjuvant medications on neuromodulation associated with peripheral nerve stimulation. However, the rats used in those specific experiments underwent a variety of invasive treatments and surgery. Therefore, separate studies from those other manipulations should be conducted in order to accurately assess how baclofen affects responses to bladder distention (UBD). Given the growing clinical concerns about opioid overdose and addiction, it's also critical to specify whether non-opioid drugs that are licensed for usage in humans can be used to treat certain forms of pain, including bladder discomfort [19].
Several basic science papers indicate that systemic or intraspinal administration of baclofen reduces pain perception. It is known to generate analgesia on its own, as shown in mice and rats utilizing hot plate, tail movement, and acetic acid-induced torsion [20-23]. Baclofen also causes analgesia in primates in the formalin test [24]. In models of neuropathic pain brought on by chemotherapy, Baclofen causes a notable but varying analgesia [25]. It is indicated to provide peripheral analgesic immpacts in a mouse model of arthritis [23]. Humans have explicitly utilized baclofen as an analgesic for neuropathic symptoms connected to the cranial nerve, such as trigeminal neuralgia [17]. It may also be effective in treating postherpetic neuralgia in the facial areas, according to anecdotal results [18]. In humans, spinal administration of baclofen has also shown short-term analgesic impacts for post-stroke and spinal cord injury pain [26]. Additionally, it relieves pain following surgery, usually by intensifying the effects of opioids [26-28].
Baclofen isn’t used extensively to treat non-neuropathic pain in humans, despite these encouraging clinical and basic scientific findings. This is regrettable as baclofen could also have beneficial impacts on lowering opiate use and dependence. Baclofen has been demonstrated to reverse behavioral sensitization to morphine, prevent the resurgence of heroin-seeking behavior [30-31], improve the extinction of opioid- and methamphetamine-induced conditioned place preference [32-33], and reduce heroin-seeking behavior in rat models in a dose-dependent manner [29]. The impacts of baclofen on reward and dependence systems are especially significant in light of the current societal concerns around opiate misuse. Therefore, administarting an effective non-opioid medicine (or supplementary therapy) like baclofen as a substitute for large dosages of opioids is both desirable and morally essential [24].
Baclofen in Children: Its Effect on Urination and Muscle Spasms
About 40% of children who consult pediatric urologists have dysuria (DV), a common clinical condition [34]. The International Childhood Continence Society (ICCS) currently uses the phrase "children with dysuria typically contract their urethral sphincter during urination." [35, 36, 37], this is how the term “dysuria” is used. The cause may be complex and may involve acquired behavior, continuation of a childhood pattern, delayed maturation, or, to a lesser extent, congenital or genetic elements [38]. Numerous symptoms can be brought on by dysuria, including storage symptoms (incontinence, urgency, frequency) and voiding symptoms (reduced stream force, frequency, lack strain, feeling of incomplete bladder emptying) [39]. Furthermore, it might be the cause of recurring UTIs, acute or chronic urine retention, and, in severe situations, upper and lower urinary tract decompensation [40]. Several reports of domestic violence in children have been documented [41]. To date, there is no specific treatment for domestic violence in children [39]. Non-pharmacological treatments such as biofeedback and behavioral therapies may help some of these children.
Children and their families are typically educated, fluid intake is maintained, voiding frequently to prevent bladder distention, toileting is corrected, and an optimal bowel emptying program is established as part of behavioral therapy [39,42]. A conventional therapy session may involve urine flow testing, 1 hr electromyography session with perineal patch electrodes, and an ultrasound evaluation of postvoid residual pee volume [43]. However, non-pharmacological treatment is recommended as an adjunctive therapy because not all patients respond to it. As far as we know, no pharmacological treatment for DV in children has been approved [39]. The bladder outlet and body of the bladder (e.g., using anticholinergic medications) are potential targets for pharmacological treatment of DV [34]. Although antimuscarinic medications wereeffective in treating hyperactive detrusor muscles, muscarinic and cholinergic agonists, such as bethanechol, weren’t demonstrated to be beneficial in addressing bladder emptying issues in children with DV.
In an effort to solve this issue, research has recently concentrated on medications that alter bladder outflow. Despite multiple instances of selective alpha-blocker therapy in early ages people with incomplete bladder emptying [44], alpha-blockers are not permitted for use in children with lower urinary tract dysfunction [36].
Intravesical injection of botulinum toxin is another pharmacological strategy to aid bladder emptying. Botulinum toxin is used to treat dyssynergia between the external sphincter and detrusor muscles in children with a number of positive results [45-46]. The evaluation and treatment of DV is influenced by the link between bowel and bladder problems. Because the pelvic floor muscles are unable to relax, DV often coexists with faecal retention, either with or without faecal incontinence [38].
Gamma-aminobutyric acid (GABA)--containing neurons affect the bladder and urethra. The external urethral sphincter is relaxed by GABA-reactive immune neurons in the sacral spinal cord, which receive inputs from the pontine micturition center [47-48]. This approach states that baclofen can be administered intrathecally to relax the urethral sphincter [38]. According to Miyazato et al., GABA, an inhibitory neurotransmitter found in the central nervous system, is crucial for the inhibitory modulation of bladder contractions [47]. Therefore, baclofen, a GABA-stimulating medication, works therapeutically through the two previously mentioned mechanisms. Baclofen is prescribed to children to treat symptoms of cerebral spasticity, especially when it is caused by infantile cerebral palsy, after cerebrovascular accidents, or in the manifestation of degenerative or neoplastic brain disease [48]. Initially, paraplegic individuals with dyssynergia received an intrathecal injection of baclofen to relieve external urethral sphincter spasm [49]. The positive effect of baclofen was then verified in a study of women with anal disc herniation [37].
When baclofen is used to treat disorders like muscle spasms brought on by multiple sclerosis or cerebral palsy, it may have an impact on the lower urinary tract in children. Baclofen can lead to improved bladder control and reduced urinary symptoms associated with neurological conditions, but it should be closely monitored to ensure that side effects such as involuntary urination or difficulty urinating do not occur [34].
Intraventricular hemorrhage during the prenatal period is often associated with cerebral palsy, a non-progressive brain lesion that occurs during the first two years of life [50]. The majority of patients have a movement disorder manifested by hypertonia, spasticity, or dystonia [50-51]. Multiple organ systems are impaired as a result of these movement disorders, which also affect striated muscles throughout the body. Cerebral palsy patients have chronic co-morbidities that necessitate polypharmacy. Bowel and bladder dysfunction is quite common, and toileting is affected by concomitant movement disorders, polypharmacy, and cognitive and physical impairment. Urination is dministrated by a complex neurological network that includes the brain, spinal cord, peripheral bladder nerves, and the muscles of the urinary sphincter [52].
Anywhere along this pathway, disruption of information transmission can lead to urinary dysfunction, sometimes referred to as “neurogenic bladder.” [54] Neurogenic bladders are traditionally described as either a large, high-capacity bladder that cannot empty or a small, spastic bladder caused by detrusor-sphincter dysfunction (DSD). Neurogenic bladder develops when the neural connections that govern bladder storage and voluntary urination are damaged [55-56]. A neurogenic bladder raises the occurrence of urinary tract infections and cystitis, lowers quality of life, and causes social stigma. Sacral nerve stimulators (SNS), whose precise mechanism is unknown, are used to treat neurogenic bladder control because they enhance voluntary pelvic floor activity and help with bladder control by increasing sacral somatic nerve impulses that originate from the pudendal nerve through S3 stimulation [57].
Another drug thought to enhance bladder control by reducing striated sphincter stiffness is intrathecal baclofen (ITB). A gamma-aminobutyric acid (GABA) B receptor agonist, Baclofen activates both pre- and postsynaptically in the spinal cords' anterior horns. By downregulating high-voltage calcium channels, it prevents the release of neurotransmitters, which causes muscles to relax [58]. Animal studies have shown that hyperactivity of the propulsive muscle and sensory nerve disorders are caused by decreased activity of gamma-aminobutyric acid [59].
Adults with spinal cord injuries or numerous scleroses may also experience muscle spasms that baclofen can help with. Baclofen may help alleviate lower urinary tract symptoms like frequent or uncontrollable urinating, according to some research. Moreover, it is thought that Baclofen makes some relaxations for the muscles in the bladder, lessening overactivity [60].
The effect of baclofen on the urinary system can be absolutely more complicated in elders due to age-related changes in urine function. Indeed, some studies report that baclofen may improve symptoms of overactive bladder. Constipation and difficulty urinating are undoubtedly possible side effects of prolonged use, particularly if you have additional medical issues such as weak urinary muscles or an enlarged prostate. [50].
This is a quantitative research design aimed at determining the influence of using baclofen on lower urinary tract system for various age groups. The samples are prepared according to age and gender, and the data consists of responses pre- and post-treatment of the people affected by lower urinary tract issues. Sample one contains 49 men and women under 50 years of age. The third sample contains 32 female patients over 50; the second sample contains 99 male patients over 50. For each sample, "pre-treatment" denotes data collected before baclofen was administered; "post-treatment" denotes data collected after baclofen was administered.
The study investigates the changes in lower urinary tract symptoms before and after the application of baclofen using a comparative approach. Data collection will be done using clinical indicators as well as urine function-specific patient-reported outcomes, such as bladder overactivity, frequency, and urgency measures. This collection of data both before and after treatment took place over a predefined period, thus ensuring homogeneity across the samples. Ethical clearance of the study was provided by the related Institutional Review Board, ensuring that all norms concerning ethics would be maintained. Knowledgeable consent was attained from each participant before being enrolled in this study. Clinical data management had the right protocols in place, and anonymity for the participants was maintained.
This approach will enable the development of a holistic understanding of the effects of baclofen on lower urinary tract symptoms, considering data from diverse patient groups. It is expected that this knowledge will result in more specific and effective treatment programs, along with special attention to age and gender-specific groups.
Evaluate the Impact of Baclofen Treatment on Lower Urinary Tract Function Across Males and Females Below 50 Years of Age
The ANOVA technique has been adopted to assess the impact of Baclofen medication on lower urinary tract function in boys and females under 50. From this, it can be seen that the F-statistic is 173.866 and the p-value is 0.000, which implies that there is a statistically significant difference among the groups. Therefore, gender significantly influences the effect of Baclofen medicine. While the among-groups sum of squares (1,504,296.939) takes into consideration variability within each group, the between-groups sum of squares (2,724,444.898) shows significant variability related to gender differences.
The results indicate that the effects of Baclofen on lower urinary tract function in males and females under 50 are not the same. In order to effectively customize treatment approaches, the highly significant results highlight the necessity for additional research into gender-specific reactions to Baclofen.
The current study's results complement and add to the body of knowledge about baclofen's impact on lower urinary tract symptoms (LUTS). This study indicates that baclofen considerably improves LUTS, which is consistent with previous research showing its involvement in relaxing bladder muscles and relieving bladder overactivity through GABAB receptor activation [15,38,60]. In particular, the study found that patients under 50 had gender-specific reactions, with substantial differences between males and females (p-value = 0.000, F-statistic = 173.866).
This finding supports the literature that emphasizes how the drug's effects vary depending on neurological and physiological parameters [34,60]. Additionally, as previously indicated by trials showing baclofen's analgesic effects on bladder discomfort and its effectiveness in treating bladder dysfunction, the results confirm the drug's potential as a targeted treatment for LUTS [18,38,58]. However, this study emphasizes the significance of gender-specific investigations to maximize baclofen's therapeutic applicability for LUTS, in contrast to the more general focus of previous research on neuropathic and spastic disorders across age ranges [50, 60].
Evaluating The Impact of Baclofen Treatment on Lower Urinary Tract Function Across Males Above 50 Years of Age
The ANOVA approach is used to assess the impact of Baclofen use on lower urinary tract function in males over 50. A statistically significant difference is indicated by an F-statistic of 184.168 and a p-value of 0.000, indicating that the treatment had a noteworthy effect. The between-groups sum of squares (3,004,158.187) shows significant treatment-related variability, but the within-groups sum of squares (3,197,156.404) shows treatment-unrelated group variability.
Lower urinary tract function was significantly affected in men over 50 taking Baclofen. The p-value is highly significant, pointing to the importance of age-related physiological markers for the evaluation of treatment efficacy. Further mechanistic investigation could give more insights into reasons for this effect and would guide the development of other more potent therapeutic ways.
These results confirm prior research that Baclofen significantly alters lower urinary tract function, particularly treating diseases related to such symptoms as those of urination in the elderly and overactive bladder [1-2]. The ANOVA analysis also revealed that Baclofen further produced a very statistically significant effect on males over 50 years, consistent with previous findings demonstrating that it relaxes the musculature in the bladder [1-3]. It, therefore, supports the literature that baclofen lessens the spasm in a muscle action exerted by action through GAB A receptors thus ameliorating symptoms of neurogenic and overactive bladders [4-5]. Still, this is one new finding given in knowledge that relates particularly to age and identifies physiologic heterogeneity amongst elderly male which hasn't been so remarkably elaborated so far [6-7]. Further study is necessary to maximize the therapeutic benefits of Baclofen with minimal potential age-related adverse effects, a fact already pointed out in the literature [8-9].
The ANOVA approach is used to estimate the influence of Baclofen medication on lower urinary tract function in females over 50. The results indicate a statistically significant difference with a p-value of 0.000 and an F-statistic of 71.029. While the among-groups sum of squares (1,292,291.375) illustrates variability within the group unrelated to the therapy, the between-groups sum of squares (1,480,480.563) demonstrates significant variability owing to the treatment.
In conclusion, women over 50 who take Baclofen experience a notable change in lower urinary tract function. The significance of this treatment for this population is highlighted by the highly significant p-value. To improve treatment approaches, more research could examine how different ages and genders react to Baclofen.
The study's findings are in line with other studies that demonstrated baclofen significantly affects lower urinary tract function, particularly its capacity to relax bladder muscles and improve bladder control in conditions including spasticity and neurogenic bladder [47, 58]. According to the statistically significant results (p-value = 0.000, F-statistic = 71.029), baclofen has a strong therapeutic effect in females over 50, which is in line with previous studies showing its effectiveness in treating urinary symptoms across a range of demographics [34, 50, 60]. These findings support the body of research showing baclofen helps ease bladder dysfunction in both neurological and non-neurological diseases [38,58]. As previously mentioned in the literature, the study focuses the necessity of more studies into the variation of treatment effects across ages and genders [50].
Table 1: The Influence of Using Baclofen on Lower Urinary Tract Function in Both Males and Females Under 50
ANOVA | |||||
Outcome below 50 male & female | |||||
- | Sum of Squares | Df | Mean Square | F | Sig. |
Between Groups | 2724444.898 | 1 | 2724444.898 | 173.866 | 0.000 |
Within Groups | 1504296.939 | 96 | 15669.760 | - | - |
Total | 4228741.837 | 97 | - | - | - |
Table 2: The Impact of Baclofen Treatment on Lower Urinary Tract Function Across Males Above 50 Years of Age
ANOVA | |||||
Outcome male above 50 | |||||
- | Sum of Squares | df | Mean Square | F | Sig. |
Between Groups | 3004158.187 | 1 | 3004158.187 | 184.168 | 0.000 |
Within Groups | 3197156.404 | 196 | 16312.022 | - | - |
Total | 6201314.591 | 197 | - | - | - |
Table 3: The Impact of Baclofen Treatment on Lower Urinary Tract Function Across Females Above 50 Years of Age
ANOVA | |||||
Outcome female above 50 | |||||
- | Sum of Squares | df | Mean Square | F | Sig. |
Among Groups | 1480480.563 | 1 | 1480480.563 | 71.029 | 0.000 |
Within Groups | 1292291.375 | 62 | 20843.409 | - | - |
Total | 2772771.938 | 63 | - | - | - |
With a focus on males and females under and over 50, the study sought to determine how baclofen affected lower urinary tract symptoms in various age groups. Assessing the impact of baclofen upon lower urinary tract function in these subgroups was one of the study's goals. ANOVA has been carried out in regard to the quantitative research methodology of this study, showing the findings on the data of pre-and post-treatment across three different groups. Outcomes indicated clear-cut differences across lower urinary tract function by treatments, and alterations because of treatments were different depending on age and gender.
Comparisons of pre- and post-treatment alterations in lower urinary tract system between both genders gave crystal clear evidence to support significant improvement in bladder functioning. The current results indicated that baclofen significantly reduced the LUTS, overactivity, frequency, and urgency of the bladder. The interesting things are that responses to the treatments depend on both gender and age; the great improvements were obtained in males of more than 50 years old. The very low p-values, all less than 0.05, along with corresponding F-statistics confirm the efficiency of the treatment and point out that age- and gender-specific approaches are needed.
These results obviously indicate that baclofen could be a useful therapeutic agent in the administration of lower urinary tract syndromes, especially in subjects above the age of fifty years. However, the differential response of each group to the treatment indicates the need for individualized treatment programs. It is also concluded from this study that further studies are required to optimize the treatment and understand the underlying mechanism, which is highly essential in elderly patients due to their predisposition to drug side effects.
From the results, the study concluded that:
Baclofen should be considered for inclusion in treating lower urinary tract dysfunction patients, especially the elderly, due to the positive response
Further research is needed concerning the differential pharmacological response of baclofen with age and gender, as well as other modifying factors that may affect the response to this drug
Further research on the topic of the long-term effects and safety of baclofen, particularly in the elderly population, is needed to increase efficacy while minimizing potential side effects
It is necessary that clinicians periodically follow up with patients on baclofen therapy to manage its side effects and ensure the effectiveness of the treatment
Konstantinidis C, Moumtzi E, Nicolia A and Thomas C. "Intrathecal baclofen for spasticity: is there an effect on bladder function? report of three cases and review of the literature." Biomedicines 2022; vol. 10, no. 12, pp. 3266.
Aymard C et al. "Presynaptic inhibition and homosynaptic depression: a comparison between lower and upper limbs in normal human subjects and patients with hemiplegia." Brain 2000; vol. 123, pp. 1688–1702.
Brogden RN et al. "Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity." Drugs 1974; vol. 8, pp. 1–14.
Duncan GW et al. "An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions: a double-blind, cross-over study." Neurology 1976; vol. 1, pp. 441–446.
Dario A and Tomei G. "A benefit-risk assessment of baclofen in severe spinal spasticity." Drug Saf. 2004; vol. 27, pp. 799–818.
Brennan PM and Whittle IR. "Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain." Br. J. Neurosurg. 2008; vol. 22, pp. 508–519.
Price GW et al. "Are baclofen-sensitive GABAB receptors present on primary afferent terminals of the spinal cord?" Nature 1984; vol. 307, pp. 71–74.
Kaupmann K et al. "Human gamma-aminobutyric acid type B receptors are differentially expressed and regulate inwardly rectifying K+ channels." Proc. Natl. Acad. Sci. USA 1998; vol. 95, pp. 14991–14996.
Li Y et al. "Effects of baclofen on spinal reflexes and persistent inward currents in motoneurons of chronic spinal rats with spasticity." J. Neurophysiol. 2004; vol. 92, pp. 2694–2703.
Francisco GE, Latorre JM and Ivanhoe CB. "Intrathecal baclofen therapy for spastic hypertonia in chronic traumatic brain injury." Brain Inj. 2007; vol. 21, pp. 335–338.
Francisco GE, Hu MM, Boake C and Ivanhoe CB. "Efficacy of early use of intrathecal baclofen therapy for treating spastic hypertonia due to acquired brain injury." Brain Inj. 2005; vol. 19, pp. 359–364.
Rosier PF et al. "International Continence Society good urodynamic practices and terms 2016: urodynamics, uroflowmetry, cystometry and pressure-flow study." Neurourol. Urodyn. 2016; vol. 36, pp. 1243–1260.
Abrams P et al. "Neural control." In Proceedings of the incontinence: 6th international consultation on incontinence, Tokyo, Japan, 13–15 September 2016, 6th ed.; ICUD—ICS: Tokyo, Japan; 2017; pp. 259–328.
Ness TJ, Randich A, Su X, DeWitte C and Hildebrand K. "Systemic and intrathecal baclofen produce bladder antinociception in rats." BMC Urology 2021; vol. 21, pp. 1–2.
Kent CN, Park C and Lindsley CW. "Classics in chemical neuroscience: baclofen." ACS Chem. Neurosci. 2020; vol. 11, pp. 1740–1755.
Bendtsen L et al. "European academy of neurology guideline on trigeminal neuralgia." Eur. J. Neurol. 2019; vol. 26, pp. 831–849.
Ness TJ, McNaught J, Clodfelder-Miller B and Su X. "Medications used to treat bladder disorders may alter effects of neuromodulation." Neurourol. Urodyn. 2020; vol. 39, pp. 1313–1320.
Dowell D, Haegerich TM and Chou R. "CDC guideline for prescribing opioids for chronic pain—United States, 2016." MMWR 2016; vol. 65, pp. 1–52.
Citterio F, Corrandini L, Smith RD and Bertorelli R. "Nociceptin attenuates opioid and GABA-B receptor-mediated analgesia in the mouse tail-flick assay." Neurosci. Lett. 2000; vol. 292, pp. 83–86.
Dirig DM and Yaksh TL. "Intrathecal baclofen and muscimol, but not midazolam, are antinociceptive using the rat-formalin model." J. Pharm. Exp. Ther. 1996; vol. 275, pp. 219–227.
Jasmin L et al. "Analgesia and hyperalgesia from GABA-mediated modulation of the cerebral cortex." Nature 2003; vol. 424, pp. 316–320.
Kalinichev M et al. "ADX71441, a novel, potent and selective positive allosteric modulator of the GABA-B receptor, shows efficacy in rodent models of overactive bladder." Br. J. Pharmacol. 2014; vol. 171, pp. 995–1006.
Pedron VT et al. "GABA-B receptors modulate morphine antinociception: pharmacological and genetic approaches." Pharmacol. Biochem. Behav. 2019; vol. 180, pp. 11–21.
Xiao W, Naso L and Bennett GJ. "Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful neuropathies." Pain Med. 2008; vol. 9, pp. 505–517.
Taira T et al. "A new approach to control central deafferentation pain: spinal intrathecal baclofen." Stereotact. Funct. Neurosurg. 1995; vol. 65, no. 1–4, pp. 101–105.
Gordon NC et al. "Enhancement of morphine analgesia by the GABA-B agonist baclofen." Neuroscience 1995; vol. 69, pp. 345–349.
Panerai AE et al. "Baclofen prolongs the analgesic effect of fentanyl in man." Br. J. Anaesth. 1985; vol. 57, pp. 954–955.
Spano MS et al. "The GABA-B receptor agonist baclofen prevents heroin-induced reinstatement of heroin-seeking behavior in rats." Neuropharmacology 2007; vol. 52, pp. 1555–1562.
DiCiano P and Everitt BJ. "The GABA-B receptor agonist baclofen attenuates cocaine- and heroin-seeking behavior by rats." Neuropsychopharmacol. 2003; vol. 28, pp. 510–518.
Bartoletti M, Ricci F and Gaiardi M. "A GABA-B agonist reverses the behavioral sensitization to morphine in rats." Psychopharmacology 2007; vol. 192, no. 1, pp. 79–85.
Heinrichs SC et al. "Baclofen enhances extinction of opiate conditioned place preference." Behav. Brain Res. 2010; vol. 207, pp. 353–359.
Voigt RM, Herrold AA and Napier TC. "Baclofen facilitates the extinction of methamphetamine-induced conditioned place preference in rats." Behav. Neurosci. 2011; vol. 125, pp. 261–267.
Shirazi M, Jahnabadi Z and Hekmati P. "Use of baclofen in children with dysfunctional voiding: a preliminary report." Cent. Eur. J. Urol. 2018; vol. 71, no. 3, pp. 315.
Farhat W et al. "The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children." J. Urol. 2000; vol. 164, pp. 1011–1015.
Rushton HG. "Wetting and functional voiding disorders." Urol. Clin. North Am. 1995; vol. 22, pp. 75–93.
Chase J et al. "The management of dysfunctional voiding in children: a report from the standardisation committee of the International Children's Continence Society." J. Urol. 2010; vol. 183, pp. 1296–1302.
Xu D et al. "Dysfunctional voiding confirmed by transdermal perineal electromyography, and its effective treatment with baclofen in women with lower urinary tract symptoms: a randomized double-blind placebo-controlled crossover trial." BJU Int. 2007; vol. 100, pp. 588–592.
Hoebeke P et al. "One thousand video-urodynamic studies in children with non-neurogenic bladder sphincter dysfunction." BJU Int. 2001; vol. 87, pp. 575–580.
Chen P-C and Wang C-C. "Managing voiding dysfunction in young men." Urol. Sci. 2013; vol. 24, pp. 78–83.
Docimo SG. The Kelalis-King-Belman Textbook of Clinical Pediatric Urology. CRC Press; 2006.
Cain MP, Wu SD, Austin PF, Herndon CA, Rink RC. "Alpha blocker therapy for children with dysfunctional voiding and urinary retention." J Urol. 2003; vol. 170, pp. 1514–1517. doi: 10.1097/01.ju.0000085961.27403.4a.
Kramer S et al. "Double-blind placebo-controlled study of α-adrenergic receptor antagonists (doxazosin) for treatment of voiding dysfunction in the pediatric population." J Urol. 2005; vol. 173, pp. 2121–2124. doi: 10.1097/01.ju.0000157689.98314.69.
Dyer L and Franco I. "Botulinum Toxin-A therapy in pediatric urology: indications for the neurogenic and non-neurogenic neurogenic bladder." Sci World J. 2009; vol. 9, pp. 1300–1305. doi: 10.1100/tsw.2009.146.
Franco I et al. "The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children." J Urol. 2007; vol. 178, pp. 1779–1780. doi: 10.1016/j.juro.2007.03.185.
Blok BF and Holstege G. "The central control of micturition and continence: implications for urology." BJU Int. 1999; vol. 83, pp. 1–6. doi: 10.1046/j.1464-410x.83.s2.2.x.
Miyazato M et al. "Suppression of detrusor-sphincter dysynergia by GABA receptor activation in the lumbosacral spinal cord in spinal cord-injured rats." Am J Physiol Regul Integr Comp Physiol. 2008; vol. 295, pp. R336–R342. doi: 10.1152/ajpregu.90315.2008.
Miyazato M et al. "GABA receptor activation in the lumbosacral spinal cord decreases detrusor overactivity in spinal cord-injured rats." J Urol. 2008; vol. 179, pp. 1178–1183. doi: 10.1016/j.juro.2007.10.030.
Akbal C et al. "Dysfunctional voiding and incontinence scoring system: quantitative evaluation of incontinence symptoms in pediatric population." J Urol. 2005; vol. 173, pp. 969–973. doi: 10.1097/01.ju.0000152183.91888.f6.
Wang RK et al. "Intrathecal baclofen obviating the need for bladder stimulator use in a patient with secondary dystonia: illustrative case." Journal of Neurosurgery: Case Lessons. 2024; vol. 8, no. 16.
Wimalasundera N and Stevenson VL. "Cerebral palsy." Pract Neurol. 2016; vol. 16, no. 3, pp. 184–194.
Favara M, Greenspan J and Aghai ZH. "Cerebral palsy and the relationship to prematurity." In: Miller F, Bachrach S, Lennon N, O’Neil ME, eds. Cerebral Palsy. Springer International Publishing; 2020, pp. 23–36.
O’Shea M. "Cerebral palsy." Semin Perinatol. 2008; vol. 32, no. 1, pp. 35–41.
Dorsher PT and McIntosh PM. "Neurogenic bladder." Adv Urol. 2012; 2012:816274.
Panicker JN. "Neurogenic bladder: epidemiology, diagnosis, and management." Semin Neurol. 2020; vol. 40, no. 5, pp. 569–579.
Fuentes M, Magalhães J and Barroso U. "Diagnosis and management of bladder dysfunction in neurologically normal children." Front Pediatr. 2019; vol. 7, pp. 298.
Chartier-Kastler EJ et al. "Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia." J Urol. 2000; vol. 164, no. 5, pp. 1476–1480.
Price GW et al. "Are baclofen-sensitive GABA-B receptors present on primary afferent terminals of the spinal cord?" Nature. 1984; vol. 307, no. 5946, pp. 71–74.
Miyazato M et al. "Roles of glycinergic and gamma-aminobutyric-ergic mechanisms in the micturition reflex in rats." Low Urin Tract Symptoms. 2009; vol. 1, suppl 1, pp. S70–S73.
Blok BF, De Weerd H and Holstege G. "Ultrastructural evidence for a paucity of projections from the lumbosacral cord to the pontine micturition center or M-region in the cat: a new concept for the organization of the micturition reflex with the periaqueductal gray as central relay." J Comp Neurol. 1995; vol. 359, no. 2, pp. 300–309.
Download PDF
Download PDF
Download PDF
Download PDF
Download XML
